

Evelo Biosciences to Present at Upcoming Investor Conferences in November

November 7, 2018

CAMBRIDGE, Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO) ("Evelo"), a clinical stage biotechnology company developing monoclonal microbials designed to act on the gut-body network for the treatment of a wide range of diseases, today announced that management will present a corporate update at two investor conferences in November:

Stifel 2018 Healthcare Conference

Date: Wednesday, November 14, 2018

Time: 11:45 a.m. ET

Location: New York, NY

Evercore ISI HealthconX

Date: Tuesday, November 27, 2018

Time: 3:30 p.m. ET

Location: Boston, MA

Live audio webcasts of both presentations will be available on the Investors section of the Evelo website at <http://ir.evelobio.com/news-events>.

Replays of the webcasts will be available for approximately 30 days following each presentation.

About Evelo Biosciences

Evelo Biosciences, Inc. is a clinical-stage biotechnology company developing monoclonal microbials, a new modality of medicines designed to act on the gut-body network. Evelo's product candidates are orally-delivered, single strains of microbes, selected for defined pharmacological properties. They are intended to modulate systemic immunology and biology by acting on multiple naturally evolved biological pathways that link the small intestine to the rest of the body. Evelo believes that monoclonal microbials have the potential to be broadly applicable across many diseases including inflammation, cancer and autoimmune diseases.

Evelo currently has three product candidates, EDP1066 and EDP1815 for the treatment of inflammatory diseases and EDP1503 for the treatment of cancer, for which ten clinical readouts are expected during 2019 and 2020. Evelo is also advancing additional candidates through preclinical development in other disease areas.

For more information, please visit www.evelobio.com.

Contact

Evelo Biosciences

Stefan Riley

617-704-2333

stefan@evelobio.com



Source: Evelo Biosciences, Inc.